2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In Partnership With:
Conference | European Hematology Association Congress
Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.
Ibrahim Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the impact of enhanced lymphodepletion on response rates and infection severity with the allogeneic CAR-T cell therapy WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic leukemia (LBL) in a phase 1/2 trial (NCT04984356).